Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited (SHA:600329)

Market Cap	21.23B
Revenue (ttm)	7.31B
Net Income (ttm)	2.23B
Shares Out	770.09M
EPS (ttm)	2.89
PE Ratio	10.91
Forward PE	17.22
Dividend	1.28 (4.06%)
Ex-Dividend Date	Jul 12, 2024

Volume	3,484,689
Average Volume	4,595,127
Open	31.49
Previous Close	31.52
Day's Range	31.26 - 31.77
52-Week Range	26.16 - 39.05
Beta	0.79
RSI	43.02
Earnings Date	Mar 31, 2025

About SHA:600329

Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited, together with its subsidiaries, produces and sells traditional Chinese medicine, western medicine, and other products primarily in the People’s Republic of China. The company manufactures and sells of biochemical pharmaceutical products. It also engages in research and development of chinese patent medicines, chemical raw materials and preparations, and nutritional supplements. In addition, the company is involved in pharmaceutical and drug retail business. Further, it offers Suxiao ...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1981
• Employees: 4,619
• Stock Exchange: Shanghai Stock Exchange
• Ticker Symbol: 600329

Financial Performance

In 2024, SHA:600329's revenue was 7.31 billion, a decrease of -11.14% compared to the previous year's 8.22 billion. Earnings were 2.23 billion, an increase of 125.94%.